PH26151A - A-aryl-substituted-2,3-dihydro-imidazo(1,2-a)furo and thieno pyridines pharmaceutical compositions containing the same and method of use thereof - Google Patents

A-aryl-substituted-2,3-dihydro-imidazo(1,2-a)furo and thieno pyridines pharmaceutical compositions containing the same and method of use thereof Download PDF

Info

Publication number: PH26151A
Authority: PH; Philippines
Prior art keywords: formula; compound according; compound; pharmaceutically acceptable; paf
Prior art date: 1988-05-05

Application number

PH38610A

Other languages

English (en)

Inventor

William J Houlihan

Seung Hoon Cheon

Original Assignee

Sandoz Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-05

Filing date

1989-05-04

Publication date

1992-03-18

1989-05-04 Application filed by Sandoz Pharmaceuticals Corp filed Critical Sandoz Pharmaceuticals Corp

1992-03-18 Publication of PH26151A publication Critical patent/PH26151A/en

Links

238000000034 method Methods 0.000 title claims description 22
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
229940125670 thienopyridine Drugs 0.000 title description 3
239000002175 thienopyridine Substances 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims abstract description 121
239000002253 acid Substances 0.000 claims description 38
150000003839 salts Chemical class 0.000 claims description 32
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
206010015866 Extravasation Diseases 0.000 claims description 10
230000036251 extravasation Effects 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
230000001404 mediated effect Effects 0.000 claims description 8
239000013566 allergen Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
206010006482 Bronchospasm Diseases 0.000 claims description 6
230000007885 bronchoconstriction Effects 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
125000004429 atom Chemical group 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
125000001424 substituent group Chemical group 0.000 claims description 3
241000124008 Mammalia Species 0.000 claims 2
235000010678 Paulownia tomentosa Nutrition 0.000 claims 1
240000002834 Paulownia tomentosa Species 0.000 claims 1
125000000217 alkyl group Chemical group 0.000 claims 1
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 abstract description 3
108010003541 Platelet Activating Factor Proteins 0.000 abstract description 3
239000002246 antineoplastic agent Substances 0.000 abstract description 3
239000003112 inhibitor Substances 0.000 abstract description 3
230000018044 dehydration Effects 0.000 abstract description 2
238000006297 dehydration reaction Methods 0.000 abstract description 2
235000013350 formula milk Nutrition 0.000 description 44
238000012360 testing method Methods 0.000 description 41
238000006243 chemical reaction Methods 0.000 description 23
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
206010028980 Neoplasm Diseases 0.000 description 14
239000000203 mixture Substances 0.000 description 14
239000002158 endotoxin Substances 0.000 description 12
230000005764 inhibitory process Effects 0.000 description 11
WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
239000007787 solid Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
108091003079 Bovine Serum Albumin Proteins 0.000 description 9
230000034994 death Effects 0.000 description 9
231100000517 death Toxicity 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 9
208000001953 Hypotension Diseases 0.000 description 8
239000002775 capsule Substances 0.000 description 8
230000036543 hypotension Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
229940098773 bovine serum albumin Drugs 0.000 description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
238000005534 hematocrit Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
-1 diethyl ethér Chemical compound 0.000 description 6
239000006260 foam Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000003826 tablet Substances 0.000 description 6
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 5
230000001276 controlling effect Effects 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
108010058846 Ovalbumin Proteins 0.000 description 4
230000003213 activating effect Effects 0.000 description 4
125000001931 aliphatic group Chemical group 0.000 description 4
229940092253 ovalbumin Drugs 0.000 description 4
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 4
239000002464 receptor antagonist Substances 0.000 description 4
229940044551 receptor antagonist Drugs 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
206010039491 Sarcoma Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
230000037396 body weight Effects 0.000 description 3
150000004292 cyclic ethers Chemical class 0.000 description 3
230000007423 decrease Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
229910052500 inorganic mineral Inorganic materials 0.000 description 3
210000003975 mesenteric artery Anatomy 0.000 description 3
239000011707 mineral Substances 0.000 description 3
235000010755 mineral Nutrition 0.000 description 3
239000012299 nitrogen atmosphere Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
230000009870 specific binding Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
206010018873 Haemoconcentration Diseases 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108700023400 Platelet-activating factor receptors Proteins 0.000 description 2
241000288906 Primates Species 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
230000000578 anorexic effect Effects 0.000 description 2
230000001430 anti-depressive effect Effects 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
239000000935 antidepressant agent Substances 0.000 description 2
229940005513 antidepressants Drugs 0.000 description 2
230000004872 arterial blood pressure Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000012267 brine Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
206010061428 decreased appetite Diseases 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
150000002537 isoquinolines Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
102000030769 platelet activating factor receptor Human genes 0.000 description 2
239000000047 product Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
239000011369 resultant mixture Substances 0.000 description 2
239000000523 sample Substances 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
239000000196 tragacanth Substances 0.000 description 2
235000010487 tragacanth Nutrition 0.000 description 2
229940116362 tragacanth Drugs 0.000 description 2
238000005303 weighing Methods 0.000 description 2
GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
UQJBDJHKGFRCLE-UHFFFAOYSA-N 2,3-dihydro-1h-imidazo[4,5-h]isoquinoline Chemical class C1=CN=CC2=C(NCN3)C3=CC=C21 UQJBDJHKGFRCLE-UHFFFAOYSA-N 0.000 description 1
YXYWBIKDCIYQFF-UHFFFAOYSA-N 2-(2,5-dimethylfuran-3-yl)-4,5-dihydro-1h-imidazole Chemical compound O1C(C)=CC(C=2NCCN=2)=C1C YXYWBIKDCIYQFF-UHFFFAOYSA-N 0.000 description 1
JLWMMYZWEHHTFF-UHFFFAOYSA-N 2-[6-(3-carbamimidoylphenoxy)-4-[di(propan-2-yl)amino]-3,5-difluoropyridin-2-yl]oxy-5-(2-methylpropylcarbamoyl)benzoic acid Chemical compound OC(=O)C1=CC(C(=O)NCC(C)C)=CC=C1OC1=NC(OC=2C=C(C=CC=2)C(N)=N)=C(F)C(N(C(C)C)C(C)C)=C1F JLWMMYZWEHHTFF-UHFFFAOYSA-N 0.000 description 1
125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 1
238000008940 Alkaline Phosphatase assay kit Methods 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
238000011725 BALB/c mouse Methods 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
241000700159 Rattus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
208000003443 Unconsciousness Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000007244 Zea mays Nutrition 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
238000013096 assay test Methods 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
229960001231 choline Drugs 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
LIQWHXBLFOERRD-UHFFFAOYSA-N ethyl 4-tert-butylbenzoate Chemical compound CCOC(=O)C1=CC=C(C(C)(C)C)C=C1 LIQWHXBLFOERRD-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004508 fractional distillation Methods 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
238000003304 gavage Methods 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000012010 growth Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000035874 hyperreactivity Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002513 implantation Methods 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
150000002642 lithium compounds Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
AYLOVBNEYSUPQC-UHFFFAOYSA-N methyl 4-trimethylsilylbenzoate Chemical compound COC(=O)C1=CC=C([Si](C)(C)C)C=C1 AYLOVBNEYSUPQC-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
229940100692 oral suspension Drugs 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
210000003200 peritoneal cavity Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000010118 platelet activation Effects 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012746 preparative thin layer chromatography Methods 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000008259 solid foam Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pyridine Compounds (AREA)

PH38610A 1988-05-05 1989-05-04 A-aryl-substituted-2,3-dihydro-imidazo(1,2-a)furo and thieno pyridines pharmaceutical compositions containing the same and method of use thereof PH26151A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US19056688A	1988-05-05	1988-05-05

Publications (1)

Publication Number	Publication Date
PH26151A true PH26151A (en)	1992-03-18

Family

ID=22701867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH38610A PH26151A (en)	1988-05-05	1989-05-04	A-aryl-substituted-2,3-dihydro-imidazo(1,2-a)furo and thieno pyridines pharmaceutical compositions containing the same and method of use thereof

Country Status (13)

Country	Link
EP (1)	EP0341213B1 (da)
JP (1)	JPH01319484A (da)
AT (1)	ATE118777T1 (da)
AU (1)	AU626295B2 (da)
CA (1)	CA1334754C (da)
DE (1)	DE68921239T2 (da)
DK (1)	DK218989A (da)
ES (1)	ES2069606T3 (da)
IE (1)	IE891445L (da)
IL (1)	IL90172A (da)
NZ (1)	NZ228968A (da)
PH (1)	PH26151A (da)
ZA (1)	ZA893343B (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2781482B1 (fr) *	1998-07-27	2001-08-31	Adir	Nouveaux derives de 8h-thieno-[2,3-b]pyrrolizine-8-one, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0765198B2 (ja) *	1986-06-27	1995-07-12	三洋電機株式会社	ドライエツチングプロセスの評価方法
EP0258175B1 (en) *	1986-07-14	1992-04-01	Sandoz Ag	5-hetero- or aryl-substituted-imidazo[2,1-a]isoquinolines

1989
- 1989-05-01 AT AT89810333T patent/ATE118777T1/de active
- 1989-05-01 EP EP89810333A patent/EP0341213B1/en not_active Expired - Lifetime
- 1989-05-01 DE DE68921239T patent/DE68921239T2/de not_active Expired - Fee Related
- 1989-05-01 ES ES89810333T patent/ES2069606T3/es not_active Expired - Lifetime
- 1989-05-02 JP JP1112323A patent/JPH01319484A/ja active Pending
- 1989-05-03 CA CA000598585A patent/CA1334754C/en not_active Expired - Fee Related
- 1989-05-03 NZ NZ228968A patent/NZ228968A/en unknown
- 1989-05-03 IL IL90172A patent/IL90172A/xx unknown
- 1989-05-03 IE IE891445A patent/IE891445L/xx unknown
- 1989-05-03 DK DK218989A patent/DK218989A/da not_active Application Discontinuation
- 1989-05-03 AU AU33977/89A patent/AU626295B2/en not_active Ceased
- 1989-05-04 PH PH38610A patent/PH26151A/en unknown
- 1989-05-05 ZA ZA893343A patent/ZA893343B/xx unknown

Also Published As

Publication number	Publication date
NZ228968A (en)	1992-01-29
ES2069606T3 (es)	1995-05-16
EP0341213A3 (en)	1991-05-29
IL90172A0 (en)	1989-12-15
DE68921239D1 (de)	1995-03-30
EP0341213A2 (en)	1989-11-08
IE891445L (en)	1989-11-05
AU3397789A (en)	1989-11-09
DK218989D0 (da)	1989-05-03
DK218989A (da)	1989-11-06
JPH01319484A (ja)	1989-12-25
ATE118777T1 (de)	1995-03-15
ZA893343B (en)	1991-01-30
DE68921239T2 (de)	1995-09-14
AU626295B2 (en)	1992-07-30
CA1334754C (en)	1995-03-14
EP0341213B1 (en)	1995-02-22
IL90172A (en)	1992-11-15

Publication	Publication Date	Title
KR101342014B1 (ko)	2013-12-19	유사분열 진행을 억제하기 위한 화합물
US4450164A (en)	1984-05-22	Imidazo[1,2-A]pyridines and use
KR100668400B1 (ko)	2007-01-17	테트라히드로피리도에테르
US4468400A (en)	1984-08-28	Antiulcer tricyclic imidazo [1,2-a]pyridines
EP0535529A2 (en)	1993-04-07	Indole derivatives and anti-ulcer compositions
SA99200064B1 (ar)	2006-10-11	مشتقات إيميدازو بيريدين imidazo pyridine المثبطة لإفراز الحمض المعدي acid secretion
JPH0747590B2 (ja)	1995-05-24	ナフチリジノン，ピリドンおよびキノロンの融合三環式誘導体ならびに対応するチオン類
ZA200100913B (en)	2002-05-02	New compounds.
US4992428A (en)	1991-02-12	5-aryl-substituted-2,3-dihydro-imidazo[1,2-a]furo- and thieno pyridines
CA2201097A1 (en)	1996-04-11	Anti-tumor agents
US4025630A (en)	1977-05-24	Anesthesia methods using benzopyrans and esters thereof as pre-anesthesia medication
AU616620B2 (en)	1991-10-31	Method for inhibition of erthrocyte aggregation using anellated tricyclic compounds
US6201129B1 (en)	2001-03-13	Tricyclic derivatives and their use as anti-cancer agents
JP2023538774A (ja)	2023-09-11	新規な選択的ｆｌｔ３阻害剤としての１ｈ－イミダゾ［４，５－ｈ］キナゾリン化合物
AU604739B2 (en)	1991-01-03	5-hetero- or aryl- substituted-imidazo(2,1-a) isoquinolines
CN110204546A (zh)	2019-09-06	含有二氮杂环片段的苯并噻嗪-4-酮类化合物及其制备方法
EP0237248A2 (en)	1987-09-16	2-[(2-Pyridyl)methylsulfinyl]thienoimidazoles and related compounds as antiulcer agents
KR101804169B1 (ko)	2017-12-04	몰루긴 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용 가능한 염, 및 이를 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 약학 조성물
US5141932A (en)	1992-08-25	5-Aryl-substituted-2,3-dihydro-imidazo(1,2-a)furo- and thieno pyridines
IE42161B1 (en)	1980-06-18	Pyrano-quinoline carboxylic acids,processes for their preparation and their use as pharmaceutical agents
US4680297A (en)	1987-07-14	Tricyclic positive inotropic agents
CA1334754C (en)	1995-03-14	5-aryl-substituted-2,3-dihydro-imidazo¬1,2-a\|furo and -thieno pyridines
WO1988006157A1 (en)	1988-08-25	5-HETERO- OR ARYL-SUBSTITUTED-IMIDAZO[2,1-a]ISOQUINOLINES
US4882328A (en)	1989-11-21	Thiazetidine derivatives
IL93068A (en)	1994-04-12	8,9-annelated-1,2,3,4-tetrahydro-BETA-carboline derivatives, their preparation and pharmaceutical compositions containing them